NCT06612541

Brief Summary

The goal of this proposal is to develop novel HH-SECTR technology for visualizing and quantifying diagnostic disease features in prematurely born infant retinopathy of prematurity (ROP) patients that lead to more informed clinical decision making. Providing depth-resolved vascular information has not been adequately investigated for its diagnostic potential. Furthermore, we seek to identify disease features not currently accessible by standard examination methods to better inform clinical decisions.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
46mo left

Started Feb 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress25%
Feb 2025Feb 2030

First Submitted

Initial submission to the registry

September 21, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 25, 2024

Completed
4 months until next milestone

Study Start

First participant enrolled

February 1, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2030

Last Updated

May 15, 2025

Status Verified

May 1, 2025

Enrollment Period

4 years

First QC Date

September 21, 2024

Last Update Submit

May 12, 2025

Conditions

Keywords

Retinopathy of PrematurityROPPrematurityOCT Imaging

Outcome Measures

Primary Outcomes (1)

  • Retinal imaging in pediatric ROP patients

    Real-time noninvasive optical imaging of the retina will be performed out to the ora serrata and ROP diagnostic markers will be evaluated in post-processing and compared against clinical examination

    Weekly imaging until 45 weeks, cessation of ROP screening, or first therapeutic intervention, whichever comes first

Eligibility Criteria

Age24 Weeks - 34 Weeks
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Preterm male and female infants born at 24-34 weeks gestational age and weighing \<1500g at birth.

You may qualify if:

  • Preterm male and female infants born at 24-34 weeks gestational age and weighing \<1500g at birth

You may not qualify if:

  • Infants surgically treated for ROP
  • Infants with significant health concern that would preclude noninvasive retinal imaging as noted by the primary inpatient team

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

RECRUITING

MeSH Terms

Conditions

Retinopathy of PrematurityPremature Birth

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesInfant, Premature, DiseasesInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesObstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Central Study Contacts

Irina De la Huerta, MD, PhD

CONTACT

Marybeth Carter

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

September 21, 2024

First Posted

September 25, 2024

Study Start

February 1, 2025

Primary Completion (Estimated)

February 1, 2029

Study Completion (Estimated)

February 1, 2030

Last Updated

May 15, 2025

Record last verified: 2025-05

Locations